Fresenius Medical Care AG (NYSE:FMS) Shares Purchased by Riverwater Partners LLC

Riverwater Partners LLC increased its holdings in Fresenius Medical Care AG (NYSE:FMS) by 29.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,381 shares of the company’s stock after purchasing an additional 3,736 shares during the quarter. Riverwater Partners LLC’s holdings in Fresenius Medical Care were worth $346,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Wulff Hansen & CO. increased its stake in shares of Fresenius Medical Care by 1,809.0% in the second quarter. Wulff Hansen & CO. now owns 343,429 shares of the company’s stock worth $6,556,000 after acquiring an additional 325,439 shares during the last quarter. Triasima Portfolio Management inc. boosted its stake in shares of Fresenius Medical Care by 27.4% during the 2nd quarter. Triasima Portfolio Management inc. now owns 85,430 shares of the company’s stock worth $1,631,000 after acquiring an additional 18,360 shares in the last quarter. QRG Capital Management Inc. increased its holdings in shares of Fresenius Medical Care by 10.9% during the 2nd quarter. QRG Capital Management Inc. now owns 60,309 shares of the company’s stock valued at $1,151,000 after acquiring an additional 5,946 shares during the last quarter. Veracity Capital LLC boosted its position in Fresenius Medical Care by 172.2% during the first quarter. Veracity Capital LLC now owns 53,023 shares of the company’s stock worth $1,022,000 after purchasing an additional 33,543 shares during the period. Finally, Creative Planning raised its position in shares of Fresenius Medical Care by 18.9% in the second quarter. Creative Planning now owns 40,140 shares of the company’s stock valued at $766,000 after purchasing an additional 6,373 shares during the period. Institutional investors and hedge funds own 8.25% of the company’s stock.

Fresenius Medical Care Stock Up 0.7 %

FMS opened at $21.04 on Thursday. The company has a market capitalization of $12.35 billion, a P/E ratio of 23.64, a P/E/G ratio of 1.06 and a beta of 0.91. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.46 and a quick ratio of 1.09. The firm’s fifty day moving average price is $20.14 and its two-hundred day moving average price is $20.12. Fresenius Medical Care AG has a fifty-two week low of $16.37 and a fifty-two week high of $22.76.

Fresenius Medical Care (NYSE:FMS) last posted its earnings results on Tuesday, July 30th. The company reported $0.38 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.38. The business had revenue of $5.13 billion for the quarter, compared to analysts’ expectations of $5.28 billion. Fresenius Medical Care had a net margin of 2.72% and a return on equity of 5.48%. On average, analysts anticipate that Fresenius Medical Care AG will post 1.52 EPS for the current year.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. Truist Financial lifted their target price on shares of Fresenius Medical Care from $22.00 to $23.00 and gave the stock a “hold” rating in a report on Monday, October 7th. StockNews.com initiated coverage on Fresenius Medical Care in a research note on Tuesday, October 8th. They set a “strong-buy” rating for the company. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, one has given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $23.00.

Fresenius Medical Care Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.